Marina Protopopova

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Marina S. Protopopova
Publication record
47 papers · 3,311 citations · H-index 16

PAPERS

Development of a Novel DNA Mono-alkylator Platform for Antibody Drug Conjugates.
20241 citationsauthor #6
Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
202220 citationsauthor #15
Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells
20226 citationsauthor #9
The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
202131 citationsauthor #15
785 STING-agonist ADCs targeting tumor-associated antigens coordinate immune-mediated killing of antigen-negative cancer cells
20211 citationsauthor #11
Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
202143 citationsauthor #18
Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
202114 citationsauthor #18
Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines
202018 citationsauthor #17
Abstract 232: An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exerts both mechanisms of action on tumor cells
20193 citationsauthor #5
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
2018760 citationsauthor #3
Abstract 754: Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect
20186 citationsauthor #9
Abstract 2831: Collateral lethality: A new target for personalized oncology
20180 citationsauthor #9
Abstract 1655: Discovery and development of IACS-010759, a novel inhibitor of Complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors
20184 citationsauthor #12
MA09.10 A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC
20172 citationsauthor #6
A prospective randomized clinical trial on accuracy of plastic periodontal probes compared to conventional metal probes around dental implants
20170 citationsauthor #1
Abstract 2670: Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models
20170 citationsauthor #2
Abstract 4971: IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors
20170 citationsauthor #25
Abstract PR01: IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities
20171 citationsauthor #4
Abstract 3837: Passenger deletion of ENO1 as a collateral lethality target in cancer
20160 citationsauthor #6
Abstract A65: IACS-10759: A novel OXPHOS inhibitor that selectively kills tumors with metabolic vulnerabilities
20164 citationsauthor #1
Abstract 335: Title: IACS-010759 is a novel clinical candidate that targets AML cells by inducing a metabolic catastrophe through inhibition of oxidative phosphorylation
20161 citationsauthor #2
Abstract 4380: IACS-10759: A novel OXPHOS inhibitor which selectively kill tumors with metabolic vulnerabilities
201510 citationsauthor #1
Cho B-S, Zeng Z, Mu H, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015;126(2):222-232.
20151 citationsauthor #7
Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.
2015111 citationsauthor #8
Abstract LB-A15: IACS-010759 is a novel inhibitor of oxidative phosphorylation that selectively targets AML cells by inducing a metabolic catastrophe
20152 citationsauthor #2
Abstract 4455: Relapsed/refractory AML responds robustly to IACS-10759, a novel OXPHOS inhibitor
20150 citationsauthor #1
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
201571 citationsauthor #14
Novel Nanomolar Potency Mitochondrial Complex I Inhibitor Iacs-1131 Selectively Kills Oxphos-Dependent AML Cells
20142 citationsauthor #2
Abstract 4768: Novel peptidic CXCR4 antagonist LY2510924 disrupts the SDF-1α/CXCR4 axis resulting in anti-AML efficacyin vivo
20140 citationsauthor #5
Pronounced Anti-Leukemia Activity in Vivo of the Novel Peptidic CXCR4 Antagonist LY2510924 As a Single Agent and in Combination with Chemotherapy
20141 citationsauthor #6
Abstract 949: Identification of OXPHOS inhibitors which selectively kill tumors with specific metabolic vulnerabilities
20140 citationsauthor #17
Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer
2008165 citationsauthor #17
The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis
2007414 citationsauthor #3
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans.
200662 citationsauthor #4
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans (DOI: 10.1016/j.ccr.2006.03.028)
20064 citationsauthor #4
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
2006419 citationsauthor #10
915 MHz microwaves and 50 Hz magnetic field affect chromatin conformation and 53BP1 foci in human lymphocytes from hypersensitive and healthy persons
2005103 citationsauthor #3
Targeted Overexpression of the Transcription Factor XBP-1 in B Cells Promotes Plasma Cell and Lymphoplasmacytic Neoplasms in Transgenic Mice.
20054 citationsauthor #3
Abstracts of theses from the Nordic countries
20050 citationsauthor #1
Affect Chromatin Conformation and 53BP1Foci in Human Lymphocytes From Hypersensitive and Healthy Persons
20050 citationsauthor #3
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
2004808 citationsauthor #4
Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.
20045 citationsauthor #11
Modulation of activity of the tumour suppressor p53 by small molecules and damaged DNA
20040 citationsauthor #1
Inhibition of p53 Activity In Vitro and In Living Cells by a Synthetic Peptide Derived from its Core Domain
20036 citationsauthor #1
EBV‐encoded EBNA‐5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF‐expressing cells
200340 citationsauthor #5
Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway
2001134 citationsauthor #3
p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core.
200038 citationsauthor #2

TIMELINE

2000 38 citations

2001 134 citations

2003 46 citations

2004 813 citations

2005 107 citations

2006 485 citations

2007 414 citations

2008 165 citations

2014 3 citations

2015 195 citations

2016 5 citations

2017 3 citations

2018 770 citations

2019 3 citations

2020 18 citations

2021 89 citations

2022 26 citations

2024 1 citations

Marina Protopopova

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT